Cost-effectiveness of Prophylactic Moisturization for Atopic Dermatitis

Importance Emerging evidence suggests that the use of moisturizers on newborns and infants (ie, from birth to 6 months of age) is potentially helpful in preventing the development of atopic dermatitis. Objective To investigate the cost-effectiveness of using a daily moisturizer as prevention against atopic dermatitis among high-risk newborns. Design, Setting, and Participants In a cost-effectiveness analysis, the average cost of total-body moisturization using 7 common moisturizers from birth to 6 months of age was determined for male and female infants. We assumed the same unit of weight per moisturizer used for a given body surface area. Based on previously reported data (relative risk reduction of 50%), the incremental gain in quality-adjusted life-years (QALYs) was determined using a 6-month time window. The cost-effectiveness of each moisturizer was determined by assuming equal efficacy. A sensitivity analysis was conducted by varying the relative risk from 0.28 to 0.90. Interventions Use of prophylactic moisturizing compounds. Main Outcomes and Measures The primary outcomes were the incremental cost-effectiveness values ($/QALY) for each moisturizer in preventing atopic dermatitis during a 6-month time window. Results The calculated amount of daily all-body moisturizer needed at birth was 3.6 g (0.12 oz) per application, which increased to 6.6 g (0.22 oz) at 6 months of age. Of the 7 products evaluated, the average price was $1.07/oz (range, $0.13/oz-$2.96/oz). For a 6-month time window, the average incremental QALY benefit was 0.021. The sensitivity analysis showed that the incremental gain of QALY ranged from 0.0041 to 0.030. Petrolatum was the most cost-effective ($353/QALY [95% CI, $244-$1769/QALY) moisturizer in the cohort. Even assuming the lowest incremental QALYs for the most expensive moisturizer, the intervention was still less than $45 000/QALY. Conclusions and Relevance Overall, atopic dermatitis represents a major health expenditure and has been associated with multiple comorbidities. Daily moisturization may represent a cost-effective, preventative strategy to reduce the burden of atopic dermatitis.

[1]  A. Paller,et al.  Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. , 2016, The Journal of allergy and clinical immunology.

[2]  H. Williams,et al.  Scoping systematic review of treatments for eczema , 2016 .

[3]  J. Silverberg,et al.  Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults , 2016, The British journal of dermatology.

[4]  M. Kiely,et al.  Skin barrier impairment at birth predicts food allergy at 2 years of age. , 2016, The Journal of allergy and clinical immunology.

[5]  S. Nedorost,et al.  The Financial and Emotional Impact of Atopic Dermatitis on Children and Their Families. , 2016, The Journal of pediatrics.

[6]  A. Scheman,et al.  Hyporeactive Products 2015: An Adjunct in the Treatment of Contact Dermatitis and Other Chronic Eczemas. , 2015, Dermatitis : contact, atopic, occupational, drug.

[7]  P. Ong,et al.  The Role of Skin Barrier in the Pathogenesis of Food Allergy , 2015, Children.

[8]  H. Williams,et al.  Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention , 2014, The Journal of allergy and clinical immunology.

[9]  Takashi Sasaki,et al.  Application of moisturizer to neonates prevents development of atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[10]  J. Silverberg,et al.  Associations of Childhood Eczema Severity: A US Population-Based Study , 2014, Dermatitis : contact, atopic, occupational, drug.

[11]  Zhou Zhu,et al.  The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma , 2014, Journal of clinical & cellular immunology.

[12]  J. Schmitt,et al.  Nonallergic comorbidities of atopic eczema: an overview of systematic reviews , 2014, Allergy.

[13]  J. Silverberg,et al.  Association between atopic dermatitis and obesity in adulthood , 2012, The British journal of dermatology.

[14]  J. C. van der Wouden,et al.  Determining the Severity of Atopic Dermatitis in Children Presenting in General Practice: An Easy and Fast Method , 2009, Dermatology research and practice.

[15]  S. Weiland,et al.  Filaggrin mutations, atopic eczema, hay fever, and asthma in children. , 2008, The Journal of allergy and clinical immunology.

[16]  R. Black,et al.  Effect of Skin Barrier Therapy on Neonatal Mortality Rates in Preterm Infants in Bangladesh: A Randomized, Controlled, Clinical Trial , 2008, Pediatrics.

[17]  T. Keil,et al.  Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. , 2006, The Journal of allergy and clinical immunology.

[18]  R Garside,et al.  The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. , 2005, Health technology assessment.

[19]  C. R. Daniel,et al.  Cost of atopic dermatitis and eczema in the United States. , 2001, Journal of the American Academy of Dermatology.

[20]  Mosteller Rd.  Simplified Calculation of Body-Surface Area , 1987 .

[21]  Anthony J. Culyer,et al.  The NICE Cost-Effectiveness Threshold , 2012, PharmacoEconomics.

[22]  E. Simpson,et al.  Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. , 2011, The Journal of investigative dermatology.

[23]  A. Culyer,et al.  The NICE cost-effectiveness threshold: what it is and what that means. , 2008, PharmacoEconomics.

[24]  K. Kaulback,et al.  The Socioeconomic Impact of Atopic Dermatitis in the United States: A Systematic Review , 2008, Pediatric dermatology.

[25]  R. Mosteller.  Simplified calculation of body-surface area. , 1987, The New England journal of medicine.